These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38581424)

  • 41. 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.
    Park MA; Padera RF; Belanger A; Dubey S; Hwang DH; Veeranna V; Falk RH; Di Carli MF; Dorbala S
    Circ Cardiovasc Imaging; 2015 Aug; 8(8):. PubMed ID: 26259579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy.
    Vitarelli A; Lai S; Petrucci MT; Gaudio C; Capotosto L; Mangieri E; Ricci S; Germanò G; De Sio S; Truscelli G; Vozella F; Pergolini MS; Giordano M
    Int J Cardiol; 2018 Nov; 271():371-377. PubMed ID: 30049493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness.
    Holcman K; Kostkiewicz M; Szot W; Ćmiel B; Mróz K; Stępień A; Graczyk K; Dziewięcka E; Karabinowska-Małocha A; Sachajko Z; Podolec P; Rubiś P
    Int J Cardiovasc Imaging; 2024 Aug; 40(8):1693-1703. PubMed ID: 38856962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac "hypertrophy" phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography.
    Ferkh A; Tjahjadi C; Stefani L; Geenty P; Byth K; De Silva K; Boyd AC; Richards D; Mollee P; Korczyk D; Taylor MS; Kwok F; Kizana E; Ng ACT; Thomas L
    Front Cardiovasc Med; 2023; 10():1183485. PubMed ID: 37465456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
    Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
    ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years.
    Ioannou A; Patel RK; Razvi Y; Porcari A; Sinagra G; Venneri L; Bandera F; Masi A; Williams GE; O'Beara S; Ganesananthan S; Massa P; Knight D; Martinez-Naharro A; Kotecha T; Chacko L; Brown J; Rauf MU; Manisty C; Moon J; Lachmann H; Wechelakar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
    Circulation; 2022 Nov; 146(22):1657-1670. PubMed ID: 36325894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis.
    Stats MA; Stone JR
    Cardiovasc Pathol; 2016; 25(5):413-7. PubMed ID: 27469499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New quantitative indices of cardiac amyloidosis with
    Matsuda N; Otsuka H; Otani T; Azane S; Kunikane Y; Otomi Y; Ueki Y; Kubota M; Amano M; Yagi S; Sata M; Harada M
    Jpn J Radiol; 2023 Apr; 41(4):428-436. PubMed ID: 36449252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes.
    Vranian MN; Sperry BW; Hanna M; Hachamovitch R; Ikram A; Brunken RC; Jaber WA
    J Nucl Cardiol; 2018 Aug; 25(4):1247-1256. PubMed ID: 28050864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Updates in Cardiac Amyloidosis Diagnosis and Treatment.
    Stern LK; Kittleson MM
    Curr Oncol Rep; 2021 Mar; 23(4):47. PubMed ID: 33725199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary Data on ATTR-Amyloidosis Prevalence Among Elderly Patients With Left Ventricular Hypertrophy in Russia.
    Nikiforova TV; Charaya KV; Shchekochikhin DY; Magomedova ZM; Enokyan MS; Volovchenko AN; Khamzatkhanova AH; Starovoytova TA; Bogdanova AA; Karalkin AV; Pasha SP; Pershina ES; Grachev AE; Zhirov IV; Andreev DA
    Kardiologiia; 2024 Apr; 64(4):54-60. PubMed ID: 38742516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis.
    Tamarappoo B; Otaki Y; Manabe O; Hyun M; Cantu S; Arnson Y; Gransar H; Hayes SW; Friedman JD; Thomson L; Slomka P; Dey D; Vescio R; Patel J; Berman DS
    J Nucl Cardiol; 2020 Feb; 27(1):28-37. PubMed ID: 31172386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.
    Miller RJH; Cadet S; Mah D; Pournazari P; Chan D; Fine NM; Berman DS; Slomka PJ
    J Nucl Cardiol; 2021 Oct; 28(5):1835-1845. PubMed ID: 33689152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiology, diagnosis, and management of cardiac amyloidosis.
    Bashir Z; Younus A; Dhillon S; Kasi A; Bukhari S
    J Investig Med; 2024 Oct; 72(7):620-632. PubMed ID: 38869161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.
    Aimo A; Fabiani I; Giannoni A; Mandoli GE; Pastore MC; Vergaro G; Spini V; Chubuchny V; Pasanisi EM; Petersen C; Poggianti E; Taddei C; Castiglione V; Latrofa S; Panichella G; Sciaccaluga C; Georgiopoulos G; Passino C; Cameli M; Emdin M
    Eur Heart J Cardiovasc Imaging; 2022 Dec; 24(1):130-141. PubMed ID: 35292807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.
    Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F
    J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.
    Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP
    Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Right ventricular involvement in transthyretin amyloidosis.
    Arvidsson S; Henein MY; Wikström G; Suhr OB; Lindqvist P
    Amyloid; 2018 Sep; 25(3):160-166. PubMed ID: 30193533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.